> new at 6:00 a new york cop convicted of lying about an arrest of a journalist. 32-year-old michael ackerman arrested a "new york times" photographer in 2012. the vet claimed the flash hindered him as he made an arrest. in a bench trial the judge found the photographer was not using a flash. ackerman faces up to four years in prison. >>> charles summer is pushing legislation to establish a discounted transit fare program for college students. the discount of 25% would ease the burden for college students. schumer says some new york students pay more than a thousand dollars a year on trains, subways and buses. >>> taking a quick look at wall street, stocks gaining ground after the release of several positive earnings reports. the dow royce 217 points. the nasdaq added 87 points and s&p 500 climbed nearly 30. >>> coming up on "eyewitness news at 6:00," a dream come brooklyn. the big reward for this young man on a mission. now. chillier temperatures are fall coats, defini "many patients and their doctors unfortunately are not aware of the options available to patients with bone cancer. patients

michael jordan and santa claus. that's about it. alix: great work this morning. reportup, a new research says it has a smoking gun on one of bill ackerman'siggest holdings. wide-out yet is -- wide-out it is being called the next enron -- why valiant is being called the next enron. ♪ alix: welcome back to the bloomberg market day. valeant getting pummeled today. it shares were down almost 30% after a report by the shortselling firm citroen research asked if the company could be the next pharmaceutical enron. bill ackman lost 700 $80 million just today. here to help us sort out the details is elizabeth joining us from san francisco. what was the main point that citroen research was making in the report? reportth: we got the saying that valiant has been working with pharmacies related to fill a door essentially taking some of their products in inventory, stuffing them into the channels of fill a door and counting them as a sale. this is the first we've heard of philadore. they have said they have been working with the specialty pharma and they have the option to buy them and they have been consolidating revenues. this is a brand-new entity w